Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates: Comparative Efficiency Validation in PCSK9 Targeting
Authors:
- Nikolai A. DmitrievNDNikolai A. Dmitriev
- Petr V. ChernovPCPetr V. Chernov
- Ivan S. GongadzeIGIvan S. Gongadze
- Valeriia I. KovchinaVKValeriia I. Kovchina
- Vladimir N. IvanovVIVladimir N. Ivanov
- Artem E. GusevAGArtem E. Gusev
- Igor P. ShilovskiyISIgor P. Shilovskiy
- Ilya A. KofiadiIKIlya A. Kofiadi
- Musa R. KhaitovMKMusa R. Khaitov
Open Access
Abstract
The development and application of therapeutic oligonucleotides, such as siRNA, miRNA, ASOs and aptamers, is a rapidly growing field in biomedicine. These molecules are undergoing extensive preclinical and clinical testing, and the market for synthetic RNA drugs is expanding. However, several challenges remain, including targeted delivery and high costs associated with development, screening and production. One significant advance has been the creation of GalNAc-conjugates, which selectively target ASGPR and deliver oligonucleotides to hepatocytes. Although these conjugates have shown promising results, their widespread use is limited by the lack of effective synthesis methods. Thus, the development of new methods for the synthesis of ligand-oligonucleotide conjugates is an important task to which this study is devoted. In this study, we created a library of siRNA conjugates with the GalNAc L-96 ligand to suppress the expression of the PCSK9 gene associated with elevated LDL and an increased risk of developing cardiovascular diseases. The selection of the most effective siRNA molecules was carried out using an algorithm previously developed by our research group, which considers thermodynamic stability, predicted specificity and effectiveness. To experimentally confirm the effectiveness of conjugates, an in vitro model based on the cultivation of hepatocyte cells was developed. Optimization of the conjugate synthesis process has significantly reduced the cost of manufacturing technology, which creates the potential for efficient scaling of synthesis for transfer and application in the pharmaceutical industry. The results of the study showed that the development of the siRNA sequence optimized in silico resulted in a significant increase in the inhibitory effect of the GalNAc-siRNA conjugate compared to a compound similar to a commercial drug.Keywords
Funding Information
- Federal Medical Biological Agency of Russian Federation
This publication has 36 references indexed in Scilit:
- Off-target effects of oligonucleotides and approaches of preclinical assessmentsSLAS Discovery, 2025
- Advancement of drugs conjugated with GalNAc in the targeted delivery to hepatocytes based on asialoglycoprotein receptorCarbohydrate Research, 2025
- Improving the potency prediction for chemically modified siRNAs through insights from molecular modeling of individual sequence positionsMolecular Therapy Nucleic Acids, 2024
- Machine learning for siRNA efficiency prediction: A systematic reviewHealth Sciences Review, 2024
- From sequences to therapeutics: Using machine learning to predict chemically modified siRNA activityGenomics, 2024
- Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related DisordersMolecular Therapy Nucleic Acids, 2020
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic DrugMolecular Therapy, 2020
- Solid-phase synthesis of 5′-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistryBioorganic & Medicinal Chemistry Letters, 2015
- An algorithm for selection of functional siRNA sequencesBiochemical and Biophysical Research Communications, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001